Financings in Brief: LifeQuest Medical
This article was originally published in The Gray Sheet
LifeQuest Medical: Completes private placement of $3 mil. of 9% convertible debentures and $1 mil. in common stock with Dallas, Texas-based Renaissance Capital Group. The funding will help finance alliances by the minimally invasive surgical device company with other firms "which are expected to make a major contribution to LifeQuest's continued rapid growth," the firm states...
You may also be interested in...
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
No device-related warning letters were released by the US FDA the week of 19 January.
Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.